Pivonello, Rosario
Simeoli, Chiara
Di Paola, Nicola
Colao, Annamaria
Funding for this research was provided by:
Università degli Studi di Napoli Federico II
Article History
Accepted: 15 July 2022
First Online: 29 August 2022
Declarations
:
: R.P. has received research support to Federico II University of Naples as a principal investigator for clinical trials from Corcept Therapeutics, HRA Pharma, Novartis Pharma, Recordati and Strongbridge Biopharma; has received different research support to Federico II University of Naples from Novartis Pharma and Strongbridge Biopharma; and has received occasional consulting honoraria from Corcept Therapeutics, HRA Pharma, Novartis Pharma, Recordati and Strongbridge Biopharma. C.S. has received occasional consulting honoraria from Bresmed Health Solutions. N.D.P. has nothing to disclose. A.C. has received research support to Federico II University of Naples as a principal investigator for clinical trials from Novartis Pharma; and has received occasional consulting honoraria from Novartis Pharma, Recordati.
: Not applicable.